AKT1 and lung carcinoma: Inhibiting integrin αvβ3 signaling not only enhances radiotherapy efficacy [25,26] but also promotes lung cancer progression via the FAK/AKT/SOX2 pathway, as demonstrated by Zhou et al. [27].